<DOC>
	<DOCNO>NCT01255891</DOCNO>
	<brief_summary>To evaluate efficacy LHRH agonist adjuvant pelvic radiation therapy post radical prostatectomy patient high risk pathological feature failure . To determine freedom biochemical ( maintenance PSA le nadir + 2 ng/ml ) clinical progression rate 5 year .</brief_summary>
	<brief_title>Adjuvant Androgen Suppression Plus Radiation Therapy High-Risk Localized Adenocarcinoma Prostate</brief_title>
	<detailed_description>Same brief Summary</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Adenocarcinoma prostate treat primarily radical prostatectomy , pathologically proven lymph node negative pelvic lymphadenectomy ( N0 ) lymph node status pathologically unknown ( undissected pelvic lymph node [ Nx ] ) , i.e . lymph node dissection require ; 2 . Any type radical prostatectomy permit , include retropubic , perineal laparoscopic robotically assist . If perform , number lymph node remove per side pelvis extent pelvic lymph node dissection ( obturator vs. extend lymph node dissection ) note . There time limit date radical prostatectomy . 3 . A postradical prostatectomy entry PSA &gt; 0 &lt; 1 ng/ml least 6 week prostatectomy within 30 day registration . 4 . One follow pathologic/chemical classification : T3N0/Nx disease without positive surgical margin ; ; Gleason score 8 ; Pre prostatectomy PSA &gt; 20 ng/ml 5 . KPS &gt; 70 6 . Age ≥ 18 ; 7 . No distant metastasis , base upon follow minimum diagnostic workup : 8 . History/physical examination ( include digital rectal exam ) within 8 wks prior registration ; 9 . A CT scan MRI abdomen pelvis within 120 day prior registration ; 10 . Bone scan within 120 day prior registration ; bone scan suspicious , plain xray and/or MRI must obtain rule metastasis . 11 . Adequate bone marrow function , within 90 day prior registration , define follow : Platelets ≥ 100,000 cells/mm3 base upon CBC ; Hemoglobin ≥ 10.0 g/dl base upon CBC AST ALT &lt; 2 x upper limit normal within 90 day prior registration ; 12 . Patients must sign studyspecific inform consent prior study entry . EXCLUSION CRITERIA : 1 . A palpable prostatic fossa abnormality/mass suggestive recurrence , unless show biopsy ultrasound guidance contain cancer ; 2 . N1 patient ineligible , pelvic lymph node enlargement ≥ 1.5 cm great dimension CT scan MRI pelvis , unless enlarge lymph node sample negative ; 3 . Androgen deprivation therapy start prior prostatectomy &gt; 6 month duration ; 4 . Androgen deprivation therapy start prostatectomy prior registration ; 5 . Prior pelvic radiotherapy ; 6 . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 5 year ( example , carcinoma situ oral cavity permissible ) ; 7 . Severe , active comorbidity , define follow : History inflammatory bowel disease ; History hepatitis B C ; Blood test require determine patient hepatitis B C , unless patient report history hepatitis . Unstable angina and/or congestive heart failure require hospitalization within last 6 month ; Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration ; Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration ; Hepatic insufficiency result clinical jaundice and/or coagulation defect ; AST ALT require ; note , however , laboratory test coagulation parameter require entry protocol . Prior allergic reaction study drug ( ) involve protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>high risk localize adenocarcinoma prostate</keyword>
</DOC>